New biotech startup Yumanity targets Alzheimer’s, Parkinson’s and ALS

December 15, 2014 5:43 PM

16 0

If you got soaked this summer as part of the ice bucket challenge, you hopefully realize the need for treatments for diseases like Lou Gehrig’s Disease (ALS). Today, over 5o million people in the world suffer from such neurodegenerative diseases like Alzheimer’s, Parkinson’s, or ALS, and cost for treating those them now hovers at over $650 billion a year.

But a new Cambridge-based company, Yumanity Theraputics, which just announced its launch this morning, has brought together a powerhouse biotech team in the hopes that they’ll tackle these diseases with force.

Read more

To category page